

NOV 0.2.2006

Docket No. PRD2121USPCT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Dominique Mabire

Serial No.: 10/596.086

Art Unit:

Filed

: November 18, 2004

Examiner:

For

: 6-SUBSTITUTED 2-QUINOLINONES AND 2-QUINOXALINONES

AS POLY (ADP-RIBOSE) POLYMERASE INHIBITORS

I hereby certify that this correspondence is being deposited with the United States Poetal Service as first clace mail in an envelope addressed to: Commissioner For Patente, P.O. Box 1450, Alexandria, VA 2231-1450 on

October 30, 2006

Alana G. Kriegsman

/Alana G. Kriegsman/

(Signature)

October 30, 2006

(Date of Signature)

Mail Stop: Patent Application Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §§1.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. §1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

M

In accordance with §1.97(b), since this Information

Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)), within three months of the date of entry into the national stage of the above identified application as set forth in §1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under §1.114, no additional fee is required. In accordance with §1.129(a), this Information Disclosure Statement is being filed in connection with | the first or Second After Final Submission, therefore: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-/ the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of:

Statement in Accordance with §1.97(e) (attached): or Please charge Deposit Account No. 10-/ the fee of \$180.00 as set forth in §1.17(p). In accordance with §1.97(d), this Information Disclosure Statement is being filed after the mailing date of either a Final Action under \$1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee. Applicant(s) hereby petition(s) for consideration of this Information Disclosure Statement. Included are: Statement in Accordance with \$1.97(e) as set forth below and the fee of \$180.00 as set forth in §1.17(p). Copies of each of the references listed on the \boxtimes attached Form PTO-1449 are enclosed herewith. Copies of references listed on the attached Form PTO-1449 are enclosed herewith EXCEPT THAT: In view of the voluminous nature of references \Box [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith. If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request. Copies of only foreign patent documents and nonpatent literature are enclosed in accordance with 37 CFR 1.98 (a)(2).

ė		
	(y	
	☐ There are no listed English language.	d references which are not in the
	The relevance of the not in the English language in	nose listed references which are as follows:
		s of search report(s) from cion(s), which are listed on the EP 609 D.
	_	ollowing non-published pending be deemed relevant, which are ssion Under MPEP 609 D.
	· -	iency or credit any overpayment to PRD2121USPCT/AGK. This form is
	Sabinizocca in origination	Respectfully submitted,
		/Alana G. Kriegsman/
		Alana G. Kriegsman Reg. No. 41,747 Attorney for Applicants
	Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1495 DATED: October 30, 2006	

,

Jo Or N∈ DA



PTO/SB/08A (08-00)
Approved for use through 10/31/2002, OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it disp

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 1 of 2

to	a collection of information unless it displays	a valid OMB control number.
	Application Number	10/596,086
	Filing Date	11/18/2004
	First Named Inventor	Dominique Mabire
	Group Art Unit	1624
	Examiner Name	Z.C. Tucker
	Attorney Docket Number	PRD2121USPCT

		U.S. Patent Do	cument			
Examiner Initials	Cite No.1	Kind Code ² Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages o relevant figures appear
/ZT/		5177075		Warner-Lambert Company	01-05-1993	
					-	
					-	
	_		-		<u> </u>	
	-					
-						

		Foreign	Patent Docum	ent	Name of Patentee or	Date of Publication of Cited Document	Pages, Columns, Lines, where relevant	
Examiner Initials	Cite No. ³	Office ³	Number ⁴	KindCode ⁵	Applicant of Cited Document	mm-dd-yyyy	passages or relevant figures appear	Т6
/ZT/		EP	0371584	B1	Janssen Pharmaceutica, N.v.	06-06-1990		L
	_			-				┝
	-			+				H
								T
								Γ

1	Signature	/Zachary Tucker/	Considered	7 March 2008
•	EXAMINER:	Initial if reference considered, whether or not citation is in conformance will	h MPEP 609, Dra	w line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

I Urique citation designation number 2 See attached Kinds of U.S. Patient Documents. Either Office that issued the document, by the voletter code (WIPO Standard ST.3.). 4For Japanees patent documents, the indication of the year of the reging of the Emperor must precede the serial number of the patient document is Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 4 Application is to place a chock must here of Emplish inauguage Translation is attached.

Burdon Hox Statement. This form is estimated to back 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete the flow mith such the sent to the Chief Hormation Officer. U. Patent and Trademark Officer. U. Swahengton, D.C. 2023 T. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO. Commissioner for Patents, P.O. Box 1450, Alexandres, V. 22313-1450

PTC/SB/08A (08-00)
Approved for use through 10/31/2002. OMB 0651-0031
Patent and Trafornack Office LLS, DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond orm 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary) Sheet 2 of 2

	a collection of information unless it displays	
1	Application Number	10/596,086
ı	Filing Date	11/18/2004
ı	First Named Inventor	Dominique Mabire
ı	Group Art Unit	1624
ı	Examiner Name	C Tuebon
	Attorney Docket Number	PRD2121USPCT

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item	
Examiner's	Cite	(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s),	T ²
Initials*	No.1	publisher, city and/or country where published	
/ZT/		KULCSAR et al., "Synthesis and Study of New 4-Quinazolinone Inhibitors of the DNA Repair Enzyme Poly (ADP-ribsose) Polymerase (PARP)", ARKIVOC, XX,XX, June 11, 2003, pages 121-123, Vol. 2003, No. PART V, XP002291367.	
/ZT/		LI et al., "PARP Inhibitors", IDrugs, 2001, pages 804-812, Vol. 4, No. 7, Current Drugs Ltd., GB.	
/ZT/		WELTIN et al., "Effect of 6(5-Phenanthridinone, an Inhibitor of Poly(ADP-ribose) Polymerase, on Cultured Tumor Cells", Oncology Research, 1994, pages 399-403, Vol. 6, No. 9, El Servier Ltd., USA.	
		,	
4.1			
	-		
	_		
	-		

Examiner		Date	
Signature	/Zachary Tucker/	Considered 7 March 2008	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Burden Nov. Statement: This form is estimated to bit a 2.0 hours to complete. Time will very depending upon the needs of the individual case. Any comments on the around of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademan Office. Washington, D.C. 2023.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandra, V. 22313-1450.

¹ Unique citation designation number. 2 Applicant is to place a check mark here if English language Translation is attached.



SUBMISSION UNDER MPEP 609 D

Application Number 10/596,086
Filing Date 11/18/2004
First Named Inventor Dominique Mabire
Group Art Unit Examiner Name
Attorney Docket Number PRD2121USPCT

Pages, Columns, Lines, where relevant passages

Page 1 of 1

Name of Patentee or

			U.S. Patent Docum		
Examiner Initials	Cite No.1	Name of Patentee or Applicant of Cited Document	Number	Kind Code ² (if known)	Pages, Columns, Lines, where relevant passages or relevant figures appear
	\vdash				
	-				
	\vdash		_		
	 	, Ange			
_					

FOREIGN PATENT DOCUMENTS

Foreign Patent Document

Examiner Initials	Cite No.1	Applicant of Cited Document	Office ³	Number ⁴	KindCode ⁶	or relevant figures appear	T ⁰
					ļ		
							\perp
	<u> </u>			-	1		
				-			
		OTHER PRIOR ART - N					
Examiner 's Initials*	No.1 volume-issue number(s), publisher, city and/or country where published						T ²
/ZT/		PCT Intl. Search Report, PCT/EP2004/	013164, Ma	rch 14, 2005,			

	Examiner Signature	/Zachary Tucker/	Date Considered	7 March 2008	
--	-----------------------	------------------	--------------------	--------------	--